CardioDx is one of several molecular diagnostics companies founded by a well-known trio of West Coast VCs to be fast finding itself in the spotlight.
CardioDx - Bringing molecular diagnostics into the cardiovascular arena
CardioDx completes validation study of first-of-its-kind genomic test for coronary artery disease
PALO ALTO, Calif., August 25, 2009 – CardioDx, a cardiovascular genomic diagnostics company, announced today that the company has successfully completed its multicenter validation study for Corus(TM) CAD, the first and only gene expression test to quantify the likelihood of obstructive(1) coronary artery disease (CAD) in patients with stable chest pain. The company expects to present results of the study by the end of 2009, and will publish the results in 2010.
CardioDx completes validation study of first-of-its-kind genomic test for coronary artery disease
CardioDx, a cardiovascular genomic diagnostics company, announced today that the company has successfully completed its multicenter validation study for Corus(TM) CAD, the first and only gene expression test to quantify the likelihood of obstructive(1) coronary artery disease (CAD) in patients with stable chest pain. The company expects to present results of the study by the end of 2009, and will publish the results in 2010.
